

Results 1st Half Year 2011/12

Investor Call Mannheim, 29th September 2011



Reimund Pohl / Dr. Michael Majerus CEO / CFO





© 2011 PHOENIX Pharmahandel GmbH & Co KG

This document has been prepared by PHOENIX Pharmahandel GmbH & Co KG (the "Company" and, together with its subsidiaries and affiliates, "PHOENIX") solely in connection with the release of the results of the 1st half year 2011/12 and is being presented solely for informational purposes. No representation or warranty, express or implied, is or will be made in relation to, and no responsibility is or will be accepted by the Company or any of its respective affiliates, advisors or representatives (together, the "Parties") as to the accuracy or completeness of the information contained in this document, and nothing in this document shall be deemed to constitute such a representation or warranty. None of the Parties or their respective agents, directors, partners and employees accept any liability whatsoever (in negligence or otherwise) for any loss or damage howsoever arising from any use of this document or its contents or otherwise arising in connection therewith and no reliance should be placed on the information or statements made herein.

This document does not constitute or form part of and should not be construed as a recommendation, offer or invitation for the purchase or subscription of any securities of the Company or any subsidiary, and neither this document nor anything contained herein shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever.

The information contained in this presentation has not been subject to any independent audit or review. A portion of the information contained in this document, including all market data and trend information, is based on estimates or expectations of the Company, and there can be no assurance that these estimates or expectations are or will prove to be accurate. In addition, past performance of PHOENIX is not indicative of future performance. The future performance of PHOENIX will depend on numerous factors which are subject to uncertainty.

Certain statements contained in this presentation that are not statements of historical fact, including, without limitation, any statements preceded by, followed by or including the words "targets," "believes," "expects," "aims," "intends," "may," "anticipates," "would," "could" or similar expressions or the negative thereof, constitute forward-looking statements, notwithstanding that such statements are not specifically identified. In addition, certain statements may be contained in press releases, and in oral and written statements made by or with the approval of the Company that are not statements of historical fact and constitute forward-looking statements. Examples of forward-looking statements include, but are not limited to: (i) statements about future financial and operating results; (ii) statements of strategic objectives, business prospects, future financial condition, budgets, projected levels of production, projected costs and projected levels of revenues and profits of the Company or its management; (iii) statements of future economic performance; and (iv) statements of assumptions underlying such statements.

Forward-looking statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions which are difficult to predict and outside of the control of the management of the Company. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements. You should not place undue reliance on these forward-looking statements. All subsequent written and oral forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements referenced above. Forward-looking statements speak only as of the date on which such statements are made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statement to reflect events or circumstances after the date on which such statement is made, or to reflect the occurrence of unanticipated events. Agenda



Highlights of the 1st Half Year 2011/12



Reimund Pohl CEO

Group Financials 1st Half Year 2011/12




Dr. Michael Majerus CFO

Questions & Answers

Facing ongoing market pressure, PHOENIX is able to grow revenue and to increase gross profit






 Based on the stable development of business in the first six months of BY 2011/12, PHOENIX group has – with an above-market
 revenue growth – once more confirmed its position as leading pharmaceutical distributor in Europe

 Gross profit and gross margin significantly improved as a result of the margin-oriented sales policy, additional higher-margin revenue, and the increasing share of retail business

(mEUR)

Year-over-year developments of EBITDA and profit before tax confirm the group's solid position





The increase in EBITDA was mainly influenced by the positive development on gross profit level and the decrease in other expenses; the higher cost of personnel and the lower result from participation were overcompensated


Profit before tax is driven by the EBITDA contribution and the improvement in the financial result, mainly due to better-than-planned debt relief and the discontinuation of one-time expenses for the financial restructuring that influenced the previous year

(mEUR)

Due to the first-time adoption of IAS 19.93A, PY figures were made comparable

PHOENIX group grows above market average due to its well-balanced country portfolio





PHOENIX wholesale marketPHOENIX wholesale and retail market

Well-balanced country portfolio

→ PHOENIX is active in 23 European markets

Favorable country mix

→ PHOENIX is the undisputed market leader in the fast-growing markets in Northern and Eastern Europe while not being active in the troubled Southern European markets

Compensation of challenging developments

→ PHOENIX is able to compensate pressure from competitors (e.g. in Germany and France) as well as regulation authorities (e.g. in Germany and UK)

Growth above market average

→ PHOENIX shows a year-over-year revenue increase of 1.0% for the first half of BY 2011/2012 whereas according to IMS* the European pharmaceutical markets grew by only 0.2%



within a pre-defined budget

Acquisitions to further strengthen the wholesale market position

- → Acquisition of a 60% participation in Farcopa Distribuzione S.r.I., a small Italian wholesaler
- ➔ Increase of the participation (from 40% to 70%) in Farmaceutici Signorini S.r.I., another regional player in the Italian wholesale market

Measures to optimize the retail portfolio

- → Purposeful acquisitions and openings of pharmacies in selected retail markets
- → Successful integration of a pharmacy portfolio in the Netherlands

Activities to adjust our participation structure

- → Sale of Imgroma BV, a marketing and sales company for OTC products in the Netherlands
- → In Poland, PHOENIX continues to consider strategic alternatives; this includes discussions with external investors to find a stronger and more sustainable base for future operations

PHOENIX is well-positioned for the future; this has recently been confirmed by two rating agencies





MOODY'S INVESTORS SERVICE

Standard & Poor's

- → On 27 July 2011, the rating agency Standard & Poor's upgraded the company's rating from B+ to BB- with continuing positive outlook
- ➔ At the same time, the **bond rating** was improved from B- to B

Moody's

→ On 1 August 2011, the rating agency Moody's upgraded the company's rating from B1/stable to B1/positive



Group Financials 1st Half Year 2011/12



Dr. Michael Majerus CFO

HY P&L reflects the positive profitability development and the ending of restructuring costs



1 st HY	1 st HY	Share of	Delta in %
2010/11	2011/12	revenue	
10,769	10,878	100%	1.0%
-9,825	-9,895	-91.0%	0.7%
944	983	9.0%	4.1%
76	75	0.7%	-0.5%
-282	-274	-2.5%	
nvest. 5	2	0.0%	-67.9%
273	284	2.6%	4.0%
10	12	0.1%	21.8%
8	0	0.0%	
3	2	0.0%	-16.2%
294	298	2.7%	1.7%
-47	-47	-0.4%	-0.9%
-110	-73	-0.7%	
116	164	1.5%	41.5%
50	-50	-0 5%	0.0%
			72.6%
	2010/11 10,769 -9,825 944 76 -469 -282 10 8 3 273 10 8 3 294 -47 -110	2010/11 2011/12 10,769 10,878 -9,825 -9,895 944 983 76 75 -469 -501 -282 -274 102 273 273 284 10 12 8 0 3 2 294 298 -47 -47 -110 -73 116 164	2010/11 2011/12 revenue 10,769 10,878 100% -9,825 -9,895 -91.0% 944 983 9.0% 76 75 0.7% -469 -501 -4.6% -282 -274 -2.5% 0.0% 273 284 2.6% 10 12 0.1% 8 0 0.0% 3 2 0.0% 294 298 2.7% -47 -47 -0.4% -110 -73 -0.7% 116 164 1.5% -50 -50 -0.5%

New developments

- Gross profit significantly improved as a result of margin-oriented sales policy, additional higher-margin revenue, and the increasing share of retail business
- Improvement allows compensating increased personnel expenses, due to first time consolidation of joint venture in the Netherlands, acquisitions in Italy, and normal wage increase
- Other operative expenses reduced due to lower level of bad-debt allowances
- As PHOENIX group reduced net debt and is no longer burdened with restructuring costs, financial result and in consequence profit before tax are significantly improved
- Improving its effective tax rate, PHOENIX is able to maintain tax level despite higher profit before tax

PHOENIX group's optimized financial structure improves the financial result




Financial result	1 st HY	1 st HY	Delta
(in mEUR)	2010/11	2011/12	
Interest income	28.1	16.9	-11.2
Interest expenses	-97.3	-87.1	10.2
Interest result	-69.2	-70.2	-1.0
Net exchange effects & change in value of derivatives	-0.7	1.1	1.7
Other financial result	-40.1	-3.8	36.3
Financial result	-109.9	-72.9	37.0

New developments

- Reduction of interest income due to VEM loan repayment already in BY 2010/2011
- Lower interest expenses are mainly driven by reduced debt
- Other financial result profits from end of restructuring costs

PHOENIX continues its committed path of strengthening its balance sheet





New developments of capital structure

- Further deleveraging efforts resulted in reduced financial liabilities
- Equity ratio further improved by profit of the period. Some reducing effects due to continuous recalculation of pension liabilities according to IAS 19.93A, here especially interest effects
- Net Working Capital slightly increased, but on average NWC days still lower than previous year:
 - HY 2011/12: 39.5 days

 PY 2010/11: 42.1 days
 Inventories grow due to seasonal fluctuations. Receivables and payables increased mainly due to second Italian acquisition


Financial Liabilities
 Cash & Equivalents
 Equity
 Net Working Capital
 Other

* Due to the first-time adoption of IAS 19.93A, PY figures were made comparable.

Results of the 1st Half Year 2011/12 PHOENIX group, 09/29/2011, Mannheim, Germany

Net Debt is significantly improved compared to previous years





Significant optimization of debt structure Reduced cash position

459 mEUR VEM loan repayment

650 mEUB cash flow contribution

Y-o-Y developments

compared to 1st HY 2010/11:

506 mEUR equity increase

1st HY developments


After slight Net Debt increase in Q1 by 0.2 bnEUR, Net Debt is almost back on low level of last year end of 2,177 mEUR

Solid financial structure after refinancing provides meaningful financial flexibility



Headroom financial facilities 07/31/2011 4,500 4,000 SFA Not drawn 825 revolver 3,500 Partly not SFA Italy 3.000 750 used Bilateral 2,500 Partly not 238 line used 2,000 ABS/ 1,095 Partly not factoring used 1,500 Bond 1,000 506 500 SFA 710 term loan ٥

- Diversified financing structure
- Strong cash generation allowed reducing SFA term loan by (-100 mEUR) in Q2 2011/12
- Optimization by reallocating of 200 mEUR from SFA term loan into SFA revolver




Debt maturity profile

- Since end of last financial year PHOENIX extended maturities for 0.6 bnEUR until end of 2015
- With the extension of maturities beyond the maturity of the high yield bond banks signal their confidence in PHOENIX's credit worthiness

(mEUR)

The cumulative cash flow for the 1st half year shows a positive free cash flow



Cash flow development

- Improved profit of the period and reduced changes in working capital lead to a positive free cash flow
- Some negative effects from 'Other non-cash expenses/income, interests, taxes, and dividends'
- Cash flow from investing activities on comparable level
- As expected, the second quarter compensates the negative swing of working capital from the 1st quarter

(mEUR)

Due to the first-time adoption of IAS 19.93A, PY figures were made comparable

PHOENIX


group



	01/31/2011	07/31/2011	Delta in %	
Equity (in mEUR)	1,761.1*	1,814.4	3.0%	
Equity Ratio	23.2%	24.1%	3.9%	
Net Debt (in mEUR)	2,176.6	2,183.9	0.3%	
Gearing (Net debt/Equity)	1.24	1.20	-2.6%	
	1 st HY 2010/11 1 st	st HY 2011/12	Delta in %	•
EBITDA (in mEUR)	273.4*	284.3	4.0%	
EBITDA-Margin	2.54%	2.61%	2.9%	
Adjusted EBITDA (in mEUR)	293.6*	298.4	1.7%	
AdjEBITDA-Margin	2.73%	2.74%	0.6%	
Interest Coverage Ratio				

The price development of the PHOENIX bond reflects the increased market margins





Results of the 1st Half Year 2011/12 PHOENIX group, 09/29/2011, Mannheim, Germany

Outlook



Despite the market and regulatory pressure in some countries and struggling competitors, **PHOENIX group maintains its outlook for 2011/12**

- Revenue growth to slightly outpace the market in 2011/12
- Adjusted EBITDA 2011/12 to exceed 2010/11 level
- Selective investments in property, plant and equipment
- Reduction of net financial liabilities compared to end of 2010/11

PHOENIX group with unchanged stringent financial policy



Deleveraging strategy	 Further deleveraging is integral part of PHOENIX's financial policy and is backed by its main shareholders Net Debt/EBITDA target of around 3.0x PHOENIX is confident to reach its leverage target in the next two years
No regular dividend payments	 In line with PHOENIX's deleveraging strategy, no regular dividend payments are planned for the next three years Loan and bond documentation also include dividend restrictions
Carefully managed acquisition activity	 PHOENIX's growth strategy is focused on above market organic growth Profitable and financially sound add-on acquisitions (mainly pharmacies) may also be pursued, but only within a predefined acquisition budget

